Trial Profile
A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) With a Food Effect Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adult Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs TBI 223 (Primary) ; TBI 223 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 07 May 2020 Status changed from active, no longer recruiting to completed.
- 25 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 25 Feb 2020 Planned number of patients changed from 48 to 72.